Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

ALOSETE Feb. 4 at 3:34 PM

$KALA could jump 100-300% with bussines combination.

1 · Reply

ALOSETE Feb. 4 at 3:07 PM

$KALA 20 k more . Thanks for the cheapest.

0 · Reply

ALOSETE Feb. 4 at 3:01 PM

$KALA Accumulating for a violent reverse.

1 · Reply

ALOSETE Feb. 4 at 2:50 PM

$KALA https://www.activistinvestor.io/

0 · Reply

ALOSETE Feb. 4 at 12:24 PM

$KALA Great opportunity here. Buy cheap. I dont see dilutiom only a bad general market. We are waiting the real resident here. Buy cheap.

0 · Reply

Holymoly1269 Feb. 4 at 9:13 AM

$KALA buying more

0 · Reply

Banelamhh Feb. 4 at 12:27 AM

$KALA so sad seeing my money get stolen and can’t do anything

1 · Reply

LoganzzRunn Feb. 3 at 11:46 PM

$KALA Whoever got conned into putting 10 million in this by Lazar at a buck just a couple days after Lazar got 99% of the company through preferreds at pennies and is now down a cool $5 million in 2 months has to be PISSED!

0 · Reply

MetalRooster Feb. 3 at 11:41 PM

$KALA Kapital laminated 😒

0 · Reply

Jjjjen Feb. 3 at 10:25 PM

$KALA need to average down here...when will it reach a dollar?

0 · Reply

KALA BIO Settles Approximately $10.6 million of Debt

Dec 4, 2025, 10:45 AM EST - 2 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Sep 29, 2025, 12:00 PM EDT - 4 months ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Aug 8, 2025, 8:00 AM EDT - 6 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 6 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 9, 2025, 8:00 AM EDT - 7 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 8 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 19, 2023, 7:12 AM EST - 3 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 10:17 AM EDT - 4 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 10:54 AM EDT - 4 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:00 AM EDT - 4 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 2, 2022, 1:25 PM EDT - 4 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 1, 2022, 9:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

ALOSETE Feb. 4 at 3:34 PM

$KALA could jump 100-300% with bussines combination.

1 · Reply

ALOSETE Feb. 4 at 3:07 PM

$KALA 20 k more . Thanks for the cheapest.

0 · Reply

ALOSETE Feb. 4 at 3:01 PM

$KALA Accumulating for a violent reverse.

1 · Reply

ALOSETE Feb. 4 at 2:50 PM

$KALA https://www.activistinvestor.io/

0 · Reply

ALOSETE Feb. 4 at 12:24 PM

$KALA Great opportunity here. Buy cheap. I dont see dilutiom only a bad general market. We are waiting the real resident here. Buy cheap.

0 · Reply

Holymoly1269 Feb. 4 at 9:13 AM

$KALA buying more

0 · Reply

Banelamhh Feb. 4 at 12:27 AM

$KALA so sad seeing my money get stolen and can’t do anything

1 · Reply

LoganzzRunn Feb. 3 at 11:46 PM

0 · Reply

MetalRooster Feb. 3 at 11:41 PM

$KALA Kapital laminated 😒

0 · Reply

Jjjjen Feb. 3 at 10:25 PM

$KALA need to average down here...when will it reach a dollar?

0 · Reply

stockpro2010 Feb. 3 at 9:42 PM

$KALA $NBY You said that last time the stock was down big on no reason and then it went up a few 100% just out of now where so did you short today, maybe it was bear trap - I don't know BUT some has been buying last 5/10 days off someone else Lets short more ah, for fun only and see what happens

0 · Reply

LoganzzRunn Feb. 3 at 9:20 PM

$KALA no doubt in my mind now is being shorted and diluted just like $NBY and no one here can convince me otherwise. Ever since both announced Atm's they have been walked down day after day after day for the last month. There hasnt been a green day on either one in a very long time. Unfortunately I see no reason for it to end. These are just shells after all.

0 · Reply

LoganzzRunn Feb. 3 at 7:10 PM

$KALA Problem here now is, sure $NBY ran big, but after what has happened since to it no one is going to hold on to Lazar stocks. If and when it ever rebounds it will be sold.

0 · Reply

Bigdubs Feb. 3 at 6:41 PM

$KALA so we shot down some Iran drone and this drops 9% ok 👌🏼makes sense for a shell to drop 🙄

1 · Reply

ALOSETE Feb. 3 at 6:20 PM

$KALA i see more polution in you than dilutiom here. Go out guy.

1 · Reply

LoganzzRunn Feb. 3 at 5:42 PM

$KALA Dilution is killing Lazar stocks it seems. Strange how he has never even tried to pr/pump any of them. Hard to execute Atm's without any news or volume to sell into.

1 · Reply

Bigdubs Feb. 3 at 3:01 PM

$KALA topping off my account today. Again what’s the theme… patience

2 · Reply

ALOSETE Feb. 3 at 2:51 PM

$KALA The majority of the float is already in the right hands, ready for Lazar to make his move.

0 · Reply

ALOSETE Feb. 3 at 2:41 PM

$KALA no cheap paper here now. Look at the volume. In Lazar we trust.

0 · Reply

ALOSETE Feb. 2 at 5:25 PM

$KALA In lazar we trust🤑🤑🤑

0 · Reply

LoganzzRunn Feb. 2 at 3:46 PM

$KALA If Lazar does what he did with $NBY I would not be surprised to see him resign his positions with Kala this week and announce the new Ceo. With Nby all of it happened within a couple days of their shareholder meeting and his 2nd investment into the company.

1 · Reply

ALOSETE Feb. 2 at 3:06 PM

$KALA float is now acumulate in strong hands. I think march will be the ignition move.

0 · Reply

Market Cap	5.21M
Revenue (ttm)	0.00
Net Income (ttm)	-38.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-3.28

Volume	1,255,900
Avg Vol	9,878,796
Day's Range	N/A - N/A
Shares Out	9.83M
Stochastic %K	0%
Beta	-2.43
Analysts	Hold
Price Target	$1.50